Enteric infections, diarrhea, and their impact on function and development

Journal of Clinical Investigation

Volumn 118, Issue 4, 2008, Pages 1277-1290

  Petri Jr , William A ^a   Miller, Mark ^b   Binder, Henry J ^c   Levine, Myron M ^d   Dillingham, Rebecca ^a   Guerrant, Richard L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c YALE UNIVERSITY   (United States)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE; MUTACOL; ROTAVIRUS VACCINE; TYPHIMVI; TYPHOID VACCINE; UNCLASSIFIED DRUG;

DEHYDRATION; DIARRHEA; ENTEROBACTERIACEAE; HUMAN; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE FUNCTION; INTESTINE INFECTION; MORTALITY; NONHUMAN; NUTRITION; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; BACTERIAL VACCINES; BIOLOGICAL MARKERS; DIARRHEA; DISEASE SUSCEPTIBILITY; ENTERITIS; HUMANS;

EID: 41849133230     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34005     Document Type: Review

References (169)

1. Kosek, M., Bern, C., and Guerrant, R.L. 2003. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 81:197-204.
2. Keusch, G.T., et al. 2006. Diarrheal diseases. In Disease control priorities in developing countries. D.T. Jamison, et al., editors. Oxford University Press. New York, New York, USA. 371-388.
3. Mara, D.D. 2003. Water, sanitation and hygiene for the health of developing nations. Public Health. 117:452-456.
4. Guerrant, R.L., Kosek, M., Lima, A.A., Lorntz, B., and Guyatt, H.L. 2002. Updating the DALYs for diarrhoeal disease. Trends Parasitol. 18:191-193.
5. Schorling, J.B., and Guerrant, R.L. 1990. Diarrhoea and catch-up growth. Lancet. 335:599-600.
6. Moore, S.R., et al. 2001. Early childhood diarrhoea and helminthiases associate with long-term linear growth faltering. Int. J. Epidemiol. 30:1457-1464.
7. Guerrant, D.I., et al. 1999. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four-seven years later in a poor urban community in northeast Brazil. Am. J. Trop. Med. Hyg. 61:707-713.
8. Lorntz, B., et al. 2006. Early childhood diarrhea predicts impaired school performance. Pediatr. Infect. Dis. J. 25:513-520.
9. Niehaus, M.D., et al. 2002. Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown. Am. J. Trop. Med. Hyg. 66:590-593.
10. Checkley, W., et al. 2004. Effect of water and sanitation on childhood health in a poor Peruvian periurban community. Lancet. 363:112-118.
11. Checkley, W., et al. 1997. Asymptomatic and symptomatic cryptosporidiosis: their acute effect on weight gain in Peruvian children. Am. J. Epidemiol. 145:156-163.
12. Checkley, W., et al. 1998. Effects of Cryptosporidium parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am. J. Epidemiol. 148:497-506.
13. Steiner, T.S., Lima, A.A., Nataro, J.P., and Guerrant, R.L. 1998. Enteroaggregative Escherichia coli produce intestinal inflammation and growth impairment and cause interleukin-8 release from intestinal epithelial cells. J. Infect. Dis. 177:88-96.
14. Mata, L.J. 1978. The children of Santa Maria Cauque: a prospective field study of health and growth. MIT Press. Cambridge, Massachusetts, USA. 395 pp.
15. Guerrant, R.L., Schorling, J.B., McAuliffe, J.F., and de Souza, M.A. 1992. Diarrhea as a cause and an effect of malnutrition: diarrhea prevents catch-up growth and malnutrition increases diarrhea frequency and duration. Am. J. Trop. Med. Hyg. 47:28-35.
16. Oria, R.B., et al. 2005. APOE4 protects the cognitive development in children with heavy diarrhea burdens in Northeast Brazil. Pediatr. Res. 57:310-316.
17. Colton, C.A., et al. 2001. Apolipoprotein E acts to increase nitric oxide production in macrophages by stimulating arginine transport. Biochim. Biophys. Acta. 1535:134-144.
18. Black, R.E., Morris, S.S., and Bryce, J. 2003. Where and why are 10 million children dying every year? Lancet. 361:2226-2234.
19. Bryce, J., Boschi-Pinto, C., Shibuya, K., and Black, R.E. 2005. WHO estimates of the causes of death in children. Lancet. 365:1147-1152.
20. Cheng, A.C., McDonald, J.R., and Thielman, N.M. 2005. Infectious diarrhea in developed and developing countries. J. Clin. Gastroenterol. 39:757-773.
21. Brooks, J.T., et al. 2006. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin. Infect. Dis. 43:393-401.
22. Steiner, T.S., Samie, A., and Guerrant, R.L. 2006. Infectious diarrhea: new pathogens and new challenges in developed and developing areas. Clin. Infect. Dis. 43:408-410.
23. Haque, R., et al. 2003. Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. Am. J. Trop. Med. Hyg. 69:398-405.
24. Clark, B., and McKendrick, M. 2004. A review of viral gastroenteritis. Curr. Opin. Infect. Dis. 17:461-469.
25. Mata, L. 1992. Diarrheal disease as a cause of malnutrition. Am. J. Trop. Med. Hyg. 47:16-27.
26. Mondal, D., Petri, W.A., Jr., Sack, R.B., Kirkpatrick, B.D., and Haque, R. 2006. Entamoeba histolytica-associated diarrheal illness is negatively associated with the growth of preschool children: evidence from a prospective study. Trans. R. Soc. Trop. Med. Hyg. 100:1032-1038.
27. Dale, D.C., and Mata, L.J. 1968. Studies of diarrheal disease in Central America. XI. Intestinal bacterial flora in malnourished children with shigellosis. Am. J. Trop. Med. Hyg. 17:397-403.
28. Crompton, D.W. 1992. Ascariasis and childhood malnutrition. Trans. R. Soc. Trop. Med. Hyg. 86:577-579.
29. Berkman, D.S., Lescano, A.G., Gilman, R.H., Lopez, S.L., and Black, M.M. 2002. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet. 359:564-571.
30. Tarleton, J.L., et al. 2006. Cognitive effects of diarrhea, malnutrition, and Entamoeba histolytica infection on school age children in Dhaka, Bangladesh. Am. J. Trop. Med. Hyg. 74:475-481.
31. Lanata, C.F., Mendoza, W., and Black, R.E. 2007. Improving diarrhoea estimates. WHO. http://www.who.int/entity/child_adolescent_health/documents/ pdfs/improving_diarrhoea_estimates.pdf.
32. Parashar, U.D., Bresee, J.S., Gentsch, J.R., and Glass, R.I. 1998. Rotavirus. Emerg. Infect. Dis. 4:561-570.
33. Kotloff, K.L., et al. 1999. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77:651-666.
34. Griffith, D.C., Kelly-Hope, L.A., and Miller, M.A. 2006. Review of reported cholera outbreaks worldwide, 1995-2005. Am. J. Trop. Med. Hyg. 75:973-977.
35. Crump, J.A., Ram, P.K., Gupta, S.K., Miller, M.A., and Mintz, E.D. 2007. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol. Infect. doi:10.1017/S0950268807009338.
36. Gupta, S.K., et al. 2007. Part III. Analysis of data gaps pertaining to enterotoxigenic Escherichia coli infections in low and medium human development index countries, 1984-2005. Epidemiol. Infect. doi:10.1017/ S095026880700934X.
37. Ram, P.K., Crump, J.A., Gupta, S.K., Miller, M.A., and Mintz, E.D. 2007. Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005. Epidemiol. Infect. doi:10.1017/S0950268807009351.
38. Velazquez, F.R., et al. 2004. Diarrhea morbidity and mortality in Mexican children: impact of rotavirus disease. Pediatr. Infect. Dis. J. 23:S149-S155.
39. Burgner, D., Jamieson, S.E., and Blackwell, J.M. 2006. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? Lancet Infect. Dis. 6:653-663.
40. Hill, A.V. 2006. Aspects of genetic susceptibility to human infectious diseases. Annu. Rev. Genet. 40:469-486.
41. Sorensen, T.I., Nielsen, G.G., Andersen, P.K., and Teasdale, T.W. 1988. Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med. 318:727-732.
42. Williams-Blangero, S., et al. 2008. Localization of multiple quantitative trait loci influencing susceptibility to infection with Ascaris lumbricoides. J. Infect. Dis. 197:66-71.
43. Peisong, G., et al. 2004. An asthma-associated genetic variant of STAT6 predicts low burden of ascaris worm infestation. Genes Immun. 5:58-62.
44. Ramsay, C.E., et al. 1999. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin. Exp. Allergy. 29:1195-1203.
45. Zambon, C.F., et al. 2005. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 29:141-152.
46. Sicinschi, L.A., et al. 2006. Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and -10 genes. Int. J. Cancer. 118:649-657.
47. Pessi, T., et al. 2005. Genetic and environmental factors in the immunopathogenesis of atopy: interaction of Helicobacter pylori infection and IL4 genetics. Int. Arch. Allergy Immunol. 137:282-288.
48. Thye, T., Burchard, G.D., Nilius, M., Muller-Myhsok, B., and Horstmann, R.D. 2003. Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. Am. J. Hum. Genet. 72:448-453.
49. Kirkpatrick, B.D., et al. 2008. Association between Cryptosporidium infection and human leukocyte antigen class I and class II alleles. J. Infect. Dis. 197:474-478.
50. Duggal, P., et al. 2007. The study of associations between Entamoeba histolytica infection and disease with single nucleotide polymorphisms (SNPS) in immune response genes. In American Society of Tropical Medicine and Hygiene (ASTMH) 56th Annual Meeting. November 4-8. Philadelphia, Pennsylvania, USA. 82.
51. Duggal, P., et al. 2004. Influence of human leukocyte antigen class II alleles on susceptibility to Entamoeba histolytica infection in Bangladeshi children. J. Infect. Dis. 189:520-526.
52. Jiang, Z.D., et al. 2003. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J. Infect. Dis. 188:506-511.
53. Jiang, Z.D., et al. 2006. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101:1112-1116.
54. Garza-Gonzalez, E., et al. 2007. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer. 7:70.
55. Glass, R.I., et al. 1985. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121:791-796.
56. Lindesmith, L., et al. 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9:548-553.
57. Oria, R.B., et al. 2007. Role of apolipoprotein E4 in protecting children against early childhood diarrhea outcomes and implications for later development. Med. Hypotheses. 68:1099-1107.
58. Corthesy, B. 2007. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J. Immunol. 178:27-32.
59. Neutra, M.R., and Kozlowski, P.A. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6:148-158.
60. Robbins, J.B., Chu, C., and Schneerson, R. 1992. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15:346-361.
61. Sztein, M.B. 2007. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45(Suppl. 1):S15-S19.
62. Sztein, M.B., Tanner, M.K., Polotsky, Y., Orenstein, J.M., and Levine, M.M. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155:3987-3993.
63. Salerno-Goncalves, R., Wahid, R., and Sztein, M.B. 2005. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect. Immun. 73:3521-3530.
64. Holmgren, J., and Czerkinsky, C. 2005. Mucosal immunity and vaccines. Nat. Med. 11:S45-S53.
65. Losonsky, G.A., et al. 1988. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. Pediatr. Infect. Dis. J. 7:388-393.
66. Czerkinsky, C., Svennerholm, A.M., Quiding, M., Jonsson, R., and Holmgren, J. 1991. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect. Immun. 59:996-1001.
67. Kantele, A. 1990. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine. 8:321-326.
68. Kantele, A., and Makela, P.H. 1991. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine. 9:423-427.
69. Losonsky, G.A., Tacket, C.O., Wasserman, S.S., Kaper, J.B., and Levine, M.M. 1993. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 61:729-733.
70. Losonsky, G.A., Kotloff, K.L., and Walker, R.I. 2003. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine. 21:562-565.
71. Kantele, A., et al. 2005. Unique characteristics of the intestinal immune system as an inductive site after antigen reencounter. J. Infect. Dis. 191:312-317.
72. Kunkel, E.J., and Butcher, E.C. 2003. Plasma-cell homing. Nat. Rev. Immunol. 3:822-829.
73. Brandtzaeg, P., and Johansen, F.E. 2005. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev. 206:32-63.
74. Haque, R., et al. 2006. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect. Immun. 74:904-909.
75. Coulson, B.S., Grimwood, K., Hudson, I.L., Barnes, G.L., and Bishop, R.F. 1992. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J. Clin. Microbiol. 30:1678-1684.
76. Fordtran, J.S. 1967. Speculations on the pathogenesis of diarrhea. Fed. Proc. 26:1405-1414.
77. Binder, H.J., and Sandle, G.I. 2007. Electrolyte transport in the mammalian colon. In Physiology of the gastrointestinal tract. L.R. Johnson, editor. Raven Press. New York, New York, USA. 2133-2172.
78. Field, M., Fromm, D., al-Awqati, Q., and Greenough, W.B., III. 1972. Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J. Clin. Invest. 51:796-804.
79. Guerrant, R.L., Chen, L.C., and Sharp, G.W. 1972. Intestinal adenyl-cyclase activity in canine cholera: correlation with fluid accumulation. J. Infect. Dis. 125:377-381.
80. Galan, J.E. 2001. Salmonella interactions with host cells: type III secretion at work. Annu. Rev. Cell Dev. Biol. 17:53-86.
81. Moss, J., and Vaughan, M. 1981. Mechanism of action of choleragen and E. coli heat-labile enterotoxin: activation of adenylate cyclase by ADP-ribosylation. Mol. Cell. Biochem. 37:75-90.
82. Mezoff, A.G., Giannella, R.A., Eade, M.N., and Cohen, M.B. 1992. Escherichia coli enterotoxin (STa) binds to receptors, stimulates guanyl cyclase, and impairs absorption in rat colon. Gastroenterology. 102:816-822.
83. Hughes, J.M., Murad, F., Chang, B., and Guerrant, R.L. 1978. Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature. 271:755-756.
84. Cassuto, J., Jodal, M., Tuttle, R., and Lundgren, O. 1981. On the role of intramural nerves in the pathogenesis of cholera toxin-induced intestinal secretion. Scand. J. Gastroenterol. 16:377-384.
85. Jodal, M., Wingren, U., Jansson, M., Heidemann, M., and Lundgren, O. 1993. Nerve involvement in fluid transport in the inflamed rat jejunum. Gut. 34:1526-1530.
86. Castagliuolo, I., et al. 1994. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology. 107:657-665.
87. Ball, J.M., Mitchell, D.M., Gibbons, T.F., and Parr, R.D. 2005. Rotavirus NSP4: a multifunctional viral enterotoxin. Viral Immunol. 18:27-40.
88. Beau, I., Cotte-Laffitte, J., Geniteau-Legendre, M., Estes, M.K., and Servin, A.L. 2007. An NSP4-dependant mechanism by which rotavirus impairs lactase enzymatic activity in brush border of human enterocyte-like Caco-2 cells. Cell Microbiol. 9:2254-2266.
89. Sansonetti, P.J., and Di Santo, J.P. 2007. Debugging how bacteria manipulate the immune response. Immunity. 26:149-161.
90. Sansonetti, P.J., Arondel, J., Cavaillon, J.M., and Huerre, M. 1995. Role of interleukin-1 in the pathogenesis of experimental shigellosis. J. Clin. Invest. 96:884-892.
91. Hecht, G. 2001. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VII. Enteropathogenic Escherichia coli: physiological alterations from an extracellular position. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G1-G7.
92. Troeger, H., Schneider, T., Epple, H., Zeitz, M., and Schulzke, J.D. 2008. Diarrheal mechanisms of human norovirus infection. Gastroenterology. In press.
93. Gill, R.K., et al. 2007. Mechanism underlying inhibition of intestinal apical Cl/OH exchange following infection with enteropathogenic E. coli. J. Clin. Invest. 117:428-437.
94. Haque, R., et al. 2007. Multiplex real-time PCR assay for detection of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp. Am. J. Trop. Med. Hyg. 76:713-717.
95. Logan, C., O'Leary, J.J., and O'Sullivan, N. 2007. Real-time reverse transcription PCR detection of norovirus, sapovirus and astrovirus as causative agents of acute viral gastroenteritis. J. Virol. Methods. 146:36-44.
96. Samie, A., Obi, C.L., Tzipori, S., Weiss, L.M., and Guerrant, R.L. 2007. Microsporidiosis in South Africa: PCR detection in stool samples of HIV-positive and HIV-negative individuals and school children in Vhembe district, Limpopo Province. Trans. R. Soc. Trop. Med. Hyg. 101:547-554.
97. Samie, A., Obi, C.L., Barrett, L.J., Powell, S.M., and Guerrant, R.L. 2007. Prevalence of Campylobacter species, Helicobacter pylori and Arcobacter species in stool samples from the Venda region, Limpopo, South Africa: studies using molecular diagnostic methods. J. Infect. 54:558-566.
98. ten Hove, R., et al. 2007. Detection of diarrhoea-causing protozoa in general practice patients in The Netherlands by multiplex real-time PCR. Clin. Microbiol. Infect. 13:1001-1007.
99. Samie, A., Obi, C.L., Dillingham, R., Pinkerton, R.C., and Guerrant, R.L. 2007. Enteroaggregative Escherichia coli in Venda, South Africa: distribution of virulence-related genes by multiplex polymerase chain reaction in stool samples of human immunodeficiency virus (HIV)-positive and HIV-negative individuals and primary school children. Am. J. Trop. Med. Hyg. 77:142-150.
100. Nataro, J.P., et al. 2006. Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin. Infect. Dis. 43:402-407.
101. Ochoa, T.J., et al. 2006. Effect of lactoferrin on enteroaggregative E. coli (EAEC). Biochem. Cell Biol. 84:369-376.
102. Guerrant, R.L., et al. 1992. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin. Microbiol. 30:1238-1242.
103. Greenberg, D.E., Jiang, Z.D., Steffen, R., Verenker, M.P., and DuPont, H.L. 2002. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J. Infect. Dis. 185:944-949.
104. Kane, S.V., et al. 2003. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am. J. Gastroenterol. 98:1309-1314.
105. Venkataraman, S., Ramakrishna, B.S., Kang, G., Rajan, D.P., and Mathan, V.I. 2003. Faecal lactoferrin as a predictor of positive faecal culture in south Indian children with acute diarrhoea. Ann. Trop. Paediatr. 23:9-13.
106. D'Inca, R., et al. 2007. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis. 22:429-437.
107. Scarpa, M., et al. 2007. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis. Colon Rectum. 50:861-869.
108. Amati, L., et al. 2006. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 28:665-681.
109. Lunn, P.G. 2000. The impact of infection and nutrition on gut function and growth in childhood. Proc. Nutr. Soc. 59:147-154.
110. Haeney, M.R., Culank, L.S., Montgomery, R.D., and Sammons, H.G. 1978. Evaluation of xylose absorption as measured in blood and urine: a one-hour blood xylose screening test in malabsorption. Gastroenterology. 75:393-400.
111. Lunn, P.G., Northrop-Clewes, C.A., and Downes, R.M. 1991. Intestinal permeability, mucosal injury, and growth faltering in Gambian infants. Lancet. 338:907-910.
112. Calain, P., et al. 2004. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine. 22:2444-2451.
113. Lucas, M.E., et al. 2005. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med. 352:757-767.
114. Murphy, T.V., et al. 2001. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:564-572.
115. Ruiz-Palacios, G.M., et al. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354:11-22.
116. Vesikari, T., et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354:23-33.
117. Lin, F.Y., et al. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
118. Mai, N.L., et al. 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
119. Kirkpatrick, B.D., et al. 2006. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine. 24:116-123.
120. Tacket, C.O., et al. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68:1196-1201.
121. Tacket, C.O., Pasetti, M.F., Sztein, M.B., Livio, S., and Levine, M.M. 2004. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. 190:565-570.
122. Hohmann, E.L., Oletta, C.A., Killeen, K.P., and Miller, S.I. 1996. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
123. Qadri, F., et al. 2007. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 25:231-238.
124. Garcia, L., et al. 2005. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect. Immun. 73:3018-3024.
125. Orr, N., et al. 2005. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect. Immun. 73:8027-8032.
126. Kotloff, K.L., et al. 2007. Safety and immunogenicity of CVD 1208S, a live, oral DguaBA Dsen Dset Shigella flexneri 2a vaccine grown on animal-free media. Hum. Vaccin. 3:268-275.
127. Katz, D.E., et al. 2004. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Immun. 72:923-930.
128. Levine, M.M., Kotloff, K.L., Barry, E.M., Pasetti, M.F., and Sztein, M.B. 2007. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5:540-553.
129. Cohen, D., et al. 1997. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 349:155-159.
130. Oaks, E.V., and Turbyfill, K.R. 2006. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine. 24:2290-2301.
131. Fries, L.F., et al. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69:4545-4553.
132. McKenzie, R., et al. 2006. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine. 24:3735-3745.
133. Xu, D.Q., Cisar, J.O., Osorio, M., Wai, T.T., and Kopecko, D.J. 2007. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection. Vaccine. 25:6167-6175.
134. Savarino, S.J., et al. 2003. Efficacy of an oral inactivated whole-cell enterotoxigenic E. coli/cholera toxin B subunit vaccine in Egyptian infants [abstract]. In The 6th Annual Conference on Vaccine Research. June 22-25. Arlington, Virginia, USA. National Foundation for Infectious Diseases. S11.
135. Daley, A., et al. 2007. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut. 56:1550-1556.
136. Barry, E.M., Wang, J., Wu, T., Davis, T., and Levine, M.M. 2006. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine. 24:3727-3734.
137. McKenzie, R., et al. 2007. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine. 25:3684-3691.
138. Tacket, C.O., Sztein, M.B., Losonsky, G.A., Wasserman, S.S., and Estes, M.K. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108:241-247.
139. Scott, D.A. 1997. Vaccines against Campylobacter jejuni. J. Infect. Dis. 176(Suppl. 2):S183-S188.
140. Sougioultzis, S., et al. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 128:764-770.
141. Boullier, S., et al. 2003. Genetically engineered enteropathogenic Escherichia coli strain elicits a specific immune response and protects against a virulent challenge. Microbes Infect. 5:857-867.
142. Houpt, E., et al. 2004. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine. 22:611-617.
143. Jenkins, M.C. 2004. Present and future control of cryptosporidiosis in humans and animals. Expert Rev. Vaccines. 3:669-671.
144. He, H., et al. 2004. The humoral and cellular immune responses in mice induced by DNA vaccine expressing the sporozoite surface protein of Cryptosporidium parvum. DNA Cell Biol. 23:335-339.
145. Konadu, E.Y., et al. 2000. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 68:1529-1534.
146. Thillainayagam, A.V., Hunt, J.B., and Farthing, M.J. 1998. Enhancing clinical efficacy of oral rehydration therapy: is low osmolality the key? Gastroenterology. 114:197-210.
147. Rao, M.C. 2004. Oral rehydration therapy: new explanations for an old remedy. Annu. Rev. Physiol. 66:385-417.
148. Binder, H.J., and Mehta, P. 1990. Characterization of butyrate-dependent electroneutral Na-Cl absorption in the rat distal colon. Pflugers Arch. 417:365-369.
149. Raghupathy, P., et al. 2006. Amylase-resistant starch as adjunct to oral rehydration therapy in children with diarrhea. J Pediatr. Gastroenterol. Nutr. 42:362-368.
150. Ramakrishna, B.S., et al. 2000. Amylase-resistant starch plus oral rehydration solution for cholera. N. Engl. J. Med. 342:308-313.
151. Ramakrishna, B.S., et al. 2008. A randomized controlled trial of glucose versus amylase resistant starch in hypo-osmolar oral rehydration solution for adult acute dehydrating diarrhea. PLos ONE. 3:e1587.
152. Sazawal, S., et al. 1995. Zinc supplementation in young children with acute diarrhea in India. N. Engl. J. Med. 333:839-844.
153. Bhatnagar, S., et al. 2004. Zinc with oral rehydration therapy reduces stool output and duration of diarrhea in hospitalized children: a randomized controlled trial. J Pediatr. Gastroenterol. Nutr. 38:34-40.
154. Hoque, K.M., and Binder, H.J. 2006. Zinc in the treatment of acute diarrhea: current status and assessment. Gastroenterology. 130:2201-2205.
155. Hoque, K.M., Rajendran, V.M., and Binder, H.J. 2005. Zinc inhibits cAMP-stimulated Cl secretion via basolateral K-channel blockade in rat ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G956-G963.
156. DeSesso, J.M., and Jacobson, C.F. 2001. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 39:209-228.
157. Vanderhoof, J.A., and Young, R.J. 2003. Enteral and parenteral nutrition in the care of patients with short-bowel syndrome. Best. Pract. Res. Clin. Gastroenterol. 17:997-1015.
158. Lima, A.A., Soares, A.M., Freire Júnior, J.E., and Guerrant, R.L. 1992. Cotransport of sodium with glutamine, alanine and glucose in the isolated rabbit ileal mucosa. Braz. J. Med. Biol. Res. 25:637-640.
159. Blikslager, A., Hunt, E., Guerrant, R., Rhoads, M., and Argenzio, R. 2001. Glutamine transporter in crypts compensates for loss of villus absorption in bovine cryptosporidiosis. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G645-G653.
160. Lima, N.L., et al. 2007. Wasting and intestinal barrier function in children taking alanyl-glutamine-supplemented enteral formula. J Pediatr. Gastroenterol. Nutr. 44:365-374.
161. Bushen, O.Y., et al. 2004. Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin. Infect Dis 38:1764-1770.
162. Carneiro-Filho, B.A., Bushen, O.Y., Brito, G.A., Lima, A.A., and Guerrant, R.L. 2003. Glutamine analogues as adjunctive therapy for infectious diarrhea. Curr. Infect. Dis. Rep. 5:114-119.
163. van Loon, F.P., et al. 1996. The effect of L-glutamine on salt and water absorption: a jejunal perfusion study in cholera in humans. Eur. J. Gastroenterol. Hepatol. 8:443-448.
164. Ribeiro, J.H., et al. 1994. Treatment of acute diarrhea with oral rehydration solutions containing glutamine. J Am. Coll. Nutr. 13:251-255.
165. Amin, H.J., et al. 2002. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J. Pediatr. 140:425-431.
166. Ottenhoff, T.H., et al. 2002. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat. Genet. 32:97-105.
167. Dunstan, S.J., et al. 2001. Genes of the class II and class III major histocompatibility complex are associated with typhoid fever in Vietnam. J. Infect. Dis. 183:261-268.
168. Mohamed, J.A., et al. 2007. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin. Infect. Dis. 44:945-952.
169. The Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447:661-678.